Gracell Biotechnologies Total Current Liabilities

Gracell Biotechnologies (GRCL) currently reports a total current liabilities of $230M as of September 2023. That compares with $250M in the prior-year period — down 6.9% year over year. Use the charts on this page to explore Gracell Biotechnologies's total current liabilities history and peer comparisons.

Gracell Biotechnologies's total current liabilities decreased from $250M to $230M — a 6.9% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gracell Biotechnologies reported $230M in total current liabilities as of September 2023. That compares with $250M in the prior-year period — down 6.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $230M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Gracell Biotechnologies, and consider following GRCL for alerts when major investors trade the stock.

Gracell Biotechnologies is classified in the Healthcare sector. On total current liabilities, it currently shows $230M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GRCL with unrelated industries.